These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 12869491)
1. Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib. Lin F; Drummond M; O'Brien S; Cervantes F; Goldman J; Kaeda J Blood; 2003 Aug; 102(3):1143. PubMed ID: 12869491 [No Abstract] [Full Text] [Related]
2. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Kantarjian HM; Cortes JE; O'Brien S; Giles F; Garcia-Manero G; Faderl S; Thomas D; Jeha S; Rios MB; Letvak L; Bochinski K; Arlinghaus R; Talpaz M Blood; 2003 Jan; 101(1):97-100. PubMed ID: 12393600 [TBL] [Abstract][Full Text] [Related]
3. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Press RD; Love Z; Tronnes AA; Yang R; Tran T; Mongoue-Tchokote S; Mori M; Mauro MJ; Deininger MW; Druker BJ Blood; 2006 Jun; 107(11):4250-6. PubMed ID: 16467199 [TBL] [Abstract][Full Text] [Related]
4. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse. Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438 [TBL] [Abstract][Full Text] [Related]
5. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765 [TBL] [Abstract][Full Text] [Related]
6. Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era. Goldman J Curr Opin Hematol; 2005 Jan; 12(1):33-9. PubMed ID: 15604889 [TBL] [Abstract][Full Text] [Related]
7. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Chu S; Xu H; Shah NP; Snyder DS; Forman SJ; Sawyers CL; Bhatia R Blood; 2005 Mar; 105(5):2093-8. PubMed ID: 15345592 [TBL] [Abstract][Full Text] [Related]
8. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334 [TBL] [Abstract][Full Text] [Related]
9. Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay. Pavlovsky C; Giere I; Moiraghi B; Pavlovsky MA; Aranguren PN; García J; Fernandez I; Bengió R; Milone J; Labanca V; Uriarte R; Lombardi V; Reinoso FG; Magariños AE; Martinez L; Murro H; Lastiri F; Pavlovsky S Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):280-5. PubMed ID: 21658656 [TBL] [Abstract][Full Text] [Related]
10. How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia? Ross DM; Hughes TP Leuk Lymphoma; 2008 Jul; 49(7):1230-1. PubMed ID: 18604711 [No Abstract] [Full Text] [Related]
11. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Sobrinho-Simões M; Wilczek V; Score J; Cross NC; Apperley JF; Melo JV Blood; 2010 Aug; 116(8):1329-35. PubMed ID: 20462961 [TBL] [Abstract][Full Text] [Related]
12. CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib. Moravcová J; Rulcová J; Polák J; Zemanová Z; Klamová H; Haskovec C Leuk Res; 2005 Nov; 29(11):1365-6. PubMed ID: 15876454 [No Abstract] [Full Text] [Related]